NASDAQ:BNTC

Benitec Biopharma (BNTC) Stock Forecast, Price & News

$3.20

+1.27 (+65.80%)

(As of 08/9/2023 ET)

Compare

Today's Range: $1.86
▼
$4.84
50-Day Range: $1.93
▼
$60.01
52-Week Range: $1.86
▼
$18.02

Volume: 26.02 million shs
Average Volume: 313,383 shs
Market Capitalization: $5.28 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $68.00

Benitec Biopharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 2,025.0% Upside
$68.00 Price Target
Short Interest: Healthy
59.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.84
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Benitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $68.00, Benitec Biopharma has a forecasted upside of 2,025.0% from its current price of $3.20.
Amount of Analyst Coverage
Benitec Biopharma has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
59.05% of the outstanding shares of Benitec Biopharma have been sold short.
Short Interest Ratio / Days to Cover
Benitec Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Benitec Biopharma has recently decreased by 57.27%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Benitec Biopharma does not currently pay a dividend.
Dividend Growth
Benitec Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BNTC.

3.8

News and Social Media Coverage

News Sentiment
Benitec Biopharma has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Benitec Biopharma this week, compared to 0 articles on an average week.
Search Interest
9 people have searched for BNTC on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
3 people have added Benitec Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Benitec Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.57% of the stock of Benitec Biopharma is held by insiders.
Percentage Held by Institutions
41.58% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Benitec Biopharma is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Benitec Biopharma is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Benitec Biopharma has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Benitec Biopharma (NASDAQ:BNTC) Stock

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

BNTC Price History

30 days | 90 days | 365 days | Advanced Chart

BNTC Stock News Headlines

August 9, 2023 | msn.com

Benitec Biopharma prices $30M equity offering

August 9, 2023 | finance.yahoo.com

Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

August 10, 2023 | Chaikin Analytics (Ad)

Fox Couldn't Air my #1 A.I. Pick - Get it Here.

50-year Wall Street Insider Marc Chaikin got invited onto Fox News to talk about A.I. - Here's what he couldn't say on television. More here.

August 2, 2023 | msn.com

Benitec Biopharma (BNTC) Price Target Increased by 1600.00% to 69.36

July 28, 2023 | barrons.com

Benitec Biopharma Inc.

July 27, 2023 | finance.yahoo.com

Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023

June 26, 2023 | marketwatch.com

Benitec Biopharma Receives FDA Clearance of IND for BB-301

June 26, 2023 | marketwatch.com

Benitec Biopharma Shares Double on FDA Clearance

August 10, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>

June 26, 2023 | msn.com

What In The World Is Going On With Benetic Biopharma (BNTC) Stock

June 26, 2023 | finance.yahoo.com

Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

May 18, 2023 | msn.com

JMP Securities Reiterates Benitec Biopharma (BNTC) Market Outperform Recommendation

May 18, 2023 | markets.businessinsider.com

JMP Securities Remains a Buy on Benitec Biopharma (BNTC)

May 16, 2023 | marketwatch.com

8-K: Benitec Biopharma Inc.

May 15, 2023 | finanznachrichten.de

Benitec Biopharma Inc.: Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

May 15, 2023 | finance.yahoo.com

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

May 8, 2023 | finance.yahoo.com

Benitec Biopharma to Present at the JMP Securities Life Sciences Conference

April 14, 2023 | nbcnews.com

More than 200 drugmakers led by Pfizer blast Texas judge's abortion pill decision

March 1, 2023 | seekingalpha.com

BNTC Benitec Biopharma Inc.

February 13, 2023 | finanznachrichten.de

Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

February 13, 2023 | finance.yahoo.com

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

January 23, 2023 | finance.yahoo.com

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

January 13, 2023 | finance.yahoo.com

Biopharma Giants Gather at JPMorgan Conference After ‘Depressing’ Year

November 10, 2022 | finanznachrichten.de

Benitec Biopharma Inc.: Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

November 10, 2022 | finance.yahoo.com

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

September 16, 2022 | finance.yahoo.com

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

September 13, 2022 | finance.yahoo.com

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

See More Headlines

Receive BNTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

BNTC Company Calendar

Last Earnings: 5/15/2023
Today: 8/10/2023
Next Earnings (Estimated): 9/01/2023
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BNTC
CUSIP: N/A
CIK: 1808898
Web: www.benitec.com
Phone: 510-780-0819
Fax: 61 (0)3 9966-9923
Employees: 18
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $68.00
High Stock Price Forecast: $68.00
Low Stock Price Forecast: $68.00
Forecasted Upside/Downside: +2,025.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($701.5306)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,210,000.00
Net Margins: N/A
Pretax Margin: -29,364.70%
Return on Equity: -255.98%
Return on Assets: -180.65%

Debt

Debt-to-Equity Ratio: 0.08
Current Ratio: 2.35
Quick Ratio: 2.35

Sales & Book Value

Annual Sales: $70,000.00
Price / Sales: 75.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.00 per share
Price / Book: 0.53

Miscellaneous

Outstanding Shares: 1,650,000
Free Float: 1,620,000
Market Cap: $5.28 million
Optionable: Not Optionable
Beta: 1.03

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Jerel A. Banks M.D. (Age 48)
Ph.D., Exec. Chairman & CEO
Comp: $799.96k

Ms. Megan Joan Boston BComm (Age 51)
CA, Dip., GAICD, Exec. Director
Comp: $456.48k

Dr. Michael Graham
Head of Discovery & Founding Scientist

Dr. Claudia Kloth
Sr. VP of Manufacturing

Key Competitors

View All Competitors

Institutional Ownership

Renaissance Technologies LLC
Sold 150,652 shares on 5/12/2023
Ownership: 0.804%

View All Institutional Transactions

BNTC Stock - Frequently Asked Questions

Should I buy or sell Benitec Biopharma stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BNTC shares.
View BNTC analyst ratings or view top-rated stocks.
What is Benitec Biopharma's stock price forecast for 2023?: 2 brokers have issued 1 year price targets for Benitec Biopharma's stock. Their BNTC share price forecasts range from $68.00 to $68.00. On average, they predict the company's share price to reach $68.00 in the next year. This suggests a possible upside of 2,025.0% from the stock's current price.
View analysts price targets for BNTC or view top-rated stocks among Wall Street analysts.
How have BNTC shares performed in 2023?: Benitec Biopharma's stock was trading at $2.89 at the beginning of the year. Since then, BNTC stock has increased by 10.7% and is now trading at $3.20.
View the best growth stocks for 2023 here.
When is Benitec Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, September 1st 2023.
View our BNTC earnings forecast.
How were Benitec Biopharma's earnings last quarter?: Benitec Biopharma Inc. (NASDAQ:BNTC) released its quarterly earnings data on Monday, May, 15th. The biotechnology company reported ($2.72) EPS for the quarter. The biotechnology company earned $0.05 million during the quarter.
When did Benitec Biopharma's stock split?: Benitec Biopharma shares reverse split before market open on Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Benitec Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP).
When did Benitec Biopharma IPO?: (BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.
What is Benitec Biopharma's stock symbol?: Benitec Biopharma trades on the NASDAQ under the ticker symbol "BNTC."
How do I buy shares of Benitec Biopharma?: Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Benitec Biopharma's stock price today?: One share of BNTC stock can currently be purchased for approximately $3.20.
How much money does Benitec Biopharma make?: Benitec Biopharma (NASDAQ:BNTC) has a market capitalization of $5.28 million and generates $70,000.00 in revenue each year. The biotechnology company earns $-18,210,000.00 in net income (profit) each year or ($701.5306) on an earnings per share basis.
How can I contact Benitec Biopharma?: Benitec Biopharma's mailing address is Level 14 114 William St, Melbourne C3, 3000. The official website for the company is www.benitec.com. The biotechnology company can be reached via phone at 510-780-0819, via email at jmorakis@mgroupsc.com, or via fax at 61 (0)3 9966-9923.

This page (NASDAQ:BNTC) was last updated on 8/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial